{"filing":{"accession_number":"0001193125-26-336716","cik":"0001590877","ticker":"RGNX","company_name":"REGENXBIO Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"rgnx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/rgnx-20260806.htm"},"events":[{"id":25548,"run_id":23188,"accession_number":"0001193125-26-336716","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"REGENXBIO issued a press release on August 6, 2026 disclosing its financial results and operational highlights for the quarter ended June 30, 2026. The disclosure includes detailed financial statements (balance sheet, revenues, R\u0026D and G\u0026A expenses, net income), cash position analysis, and forward-looking guidance on cash runway into Q4 2027. This is a standard quarterly earnings release furnished under Item 2.02, with the press release attached as Exhibit 99.1.","company_name":"REGENXBIO Inc.","ticker":"RGNX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26409,"accession_number":"0001193125-26-336716","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"REGENXBIO issued a press release on August 6, 2026 disclosing its financial results and operational highlights for the quarter ended June 30, 2026. The disclosure includes detailed financial statements (balance sheet, revenues, R\u0026D and G\u0026A expenses, net income), cash position analysis, and forward-looking guidance on cash runway into Q4 2027. This is a standard quarterly earnings release furnished under Item 2.02, with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:53:50.277047+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26409,"accession_number":"0001193125-26-336716","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"REGENXBIO issued a press release on August 6, 2026 disclosing its financial results and operational highlights for the quarter ended June 30, 2026. The disclosure includes detailed financial statements (balance sheet, revenues, R\u0026D and G\u0026A expenses, net income), cash position analysis, and forward-looking guidance on cash runway into Q4 2027. This is a standard quarterly earnings release furnished under Item 2.02, with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:53:50.277047+00:00","company_name":"REGENXBIO Inc.","ticker":"RGNX","filing_date":"2026-08-06"}]}